In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 198.75 above Mira Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 2 other companies have achieved higher Quick Ratio than Mira Pharmaceuticals Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 17 to 23.

Explain Quick Ratio?
How much Cash & cash equivalents MIRA�s has?
What are MIRA�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

MIRA Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-86.32 %	-67.94 %	-2.94 %	-87.89 %	-62.53 %
Y / Y Cash & cash equivalent Change	1010.7 %	679.79 %	289.35 %	81.83 %	-74.13 %
Quick Ratio MRQ	198.75	276.28	15.71	89.79	2.45
MIRA's Total Ranking	# 23	# 17	# 183	# 33	# 828
Seq. Current Liabilities Change	19.9 %	-95.15 %	736.57 %	-71.88 %	181.07 %
Seq. Cash & cash equivalent Change	-13.75 %	-14.72 %	46.37 %	931.64 %	-39.44 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 3
Healthcare Sector	# 3
Overall Market	# 23

Quick Ratio Statistics
High	Average	Low
276.28	44.91	0.01
(Mar 31 2026)		(Jun 30 2023)

Financial Statements
Mira Pharmaceuticals Inc 's Current Liabilities	$ 0 Millions	Visit MIRA's Balance sheet
Mira Pharmaceuticals Inc 's Cash & cash equivalent	$ 8 Millions	Visit MIRA's Balance sheet
Source of MIRA's Sales		Visit MIRA's Sales by Geography

Cumulative Mira Pharmaceuticals Inc 's Quick Ratio

MIRA's Quick Ratio for the trailling 12 Months

MIRA Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-52.72 %	-51.76 %	-58.42 %	-55 %	-36.53 %
Y / Y Cash & cash equivalent TTM Growth	304.81 %	160.76 %	53.81 %	-18.5 %	-47.01 %
Quick Ratio TTM	41.92	25.66	17.22	10.15	4.9
Total Ranking TTM	# 2337	# 2677	# 2368	# 2453	# 2794
Seq. Current Liabilities TTM Growth	-23.04 %	-6.06 %	-1.75 %	-33.44 %	-21.48 %
Seq. Cash & cash equivalent TTM Growth	25.72 %	40 %	66.61 %	38.04 %	-19.02 %

Quick ratio ranking by company, industry and sector >> Back to MIRA Financial Strength Comparisons >> Go to Compare MIRA Quick Ratio to its Competitors

On the trailing twelve months basis MIRA Cash & cash equivalent more than doubled by 1010.7 % in Q2 2026 year on year, while Current Liabilities increased to $0 millions, this led to increase in in Mira Pharmaceuticals Inc 's Quick Ratio to 41.92, above MIRA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 386 other companies have achieved higher Quick Ratio than Mira Pharmaceuticals Inc . While Quick Ratio overall ranking has improved so far to 2337, from total ranking during the twelve months ending first quarter 2026 at 2677.

Explain Quick Ratio?
How much Cash & cash equivalents MIRA�s has?
What are MIRA�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 387
Healthcare Sector	# 739
Within the Market	# 2337

trailing twelve months Quick Ratio Statistics
High	Average	Low
38.32	10.95	2.02
(Jun 30 2026)		(Dec 31 2023)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Benitec Biopharma Inc	325.45	$ 179.972 Millions	$ 0.553 Millions
Mira Pharmaceuticals Inc	198.75	$ 8.113 Millions	$ 0.041 Millions
Veradermics Inc	139.85	$ 1,635.362 Millions	$ 11.694 Millions
Enliven Therapeutics Inc	116.86	$ 1,654.850 Millions	$ 14.161 Millions
Acrivon Therapeutics Inc	104.48	$ 89.959 Millions	$ 0.861 Millions
Arca Biopharma Inc	87.05	$ 2,225.581 Millions	$ 25.566 Millions
Tango Therapeutics Inc	82.19	$ 1,668.432 Millions	$ 20.299 Millions
Contineum Therapeutics Inc	70.25	$ 458.440 Millions	$ 6.526 Millions
Sagimet Biosciences inc	61.23	$ 331.832 Millions	$ 5.419 Millions
Avalyn Pharma Inc	49.93	$ 539.733 Millions	$ 10.809 Millions
Pasithea Therapeutics Corp	49.76	$ 91.464 Millions	$ 1.838 Millions
Disc Medicine Inc	44.03	$ 1,336.770 Millions	$ 30.360 Millions

Date modified: 2026-09-03T16:20:42+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.